Literature DB >> 11321474

Effect of norcantharidin on N-acetyltransferase activity in HepG2 cells.

L T Wu1, J G Chung, J C Chen, W Tsauer.   

Abstract

The inhibition ofarylamine N-acetyltransferase (NAT) activity by norcantharidin (NCTD), the demethylated form of cantharidin, in human hepatocellular carcinoma HepG2 cells was investigated. By using high performance liquid chromatography, NAT activity on acetylation of 2-aminofluorene (AF) and p-aminobenzoic acid (PABA) were examined. Two assay systems were performed, one with cellular cytosols, the other with intact HepG2 cell suspensions. The NAT activity in HepG2 cell line was inhibited by norcantharidin in a dose-dependent manner in both types of examined systems: i.e. the greater the concentration of norcantharidin in the reaction, the greater the inhibition of NAT activities. This report is the first to show that norcantharidin has an inhibitory effect on NAT activity in HepG2 cell.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11321474     DOI： 10.1142/S0192415X01000186

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN： 0192-415X            Impact factor:   4.667


  7 in total

1.  Norcantharidin-induced apoptosis is via the extracellular signal-regulated kinase and c-Jun-NH2-terminal kinase signaling pathways in human hepatoma HepG2 cells.

Authors:  Yan-Nian Chen; Chi-Chih Cheng; Jung-Chou Chen; Wei Tsauer; Shih-Lan Hsu
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

2.  A systems biology approach reveals the role of a novel methyltransferase in response to chemical stress and lipid homeostasis.

Authors:  Elena Lissina; Brian Young; Malene L Urbanus; Xue Li Guan; Jonathan Lowenson; Shawn Hoon; Anastasia Baryshnikova; Isabelle Riezman; Magali Michaut; Howard Riezman; Leah E Cowen; Markus R Wenk; Steven G Clarke; Guri Giaever; Corey Nislow
Journal:  PLoS Genet       Date:  2011-10-20       Impact factor: 5.917

3.  A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.

Authors:  Xin-Ping Li; Wei Jing; Jian-Jun Sun; Zhong-Yan Liu; Jing-Tao Zhang; Wei Sun; Wei Zhu; Yue-Zu Fan
Journal:  BMC Cancer       Date:  2015-07-19       Impact factor: 4.430

4.  Molecular biology of cantharidin in cancer cells.

Authors:  Rolf Rauh; Stefan Kahl; Herbert Boechzelt; Rudolf Bauer; Bernd Kaina; Thomas Efferth
Journal:  Chin Med       Date:  2007-07-04       Impact factor: 5.455

5.  N-Farnesyloxy-norcantharimide inhibits progression of human leukemic Jurkat T cells through regulation of mitogen-activated protein kinase and interleukin-2 production.

Authors:  Ming-Che Chang; Jin-Yi Wu; Hui-Fen Liao; Yu-Jen Chen; Cheng-Deng Kuo
Journal:  Anticancer Drugs       Date:  2015-11       Impact factor: 2.248

6.  Comparative assessment of therapeutic safety of norcantharidin, N-farnesyloxy-norcantharimide, and N-farnesyl-norcantharimide against Jurkat T cells relative to human normal lymphoblast: A quantitative pilot study.

Authors:  Ming-Che Chang; Jin-Yi Wu; Hui-Fen Liao; Yu-Jen Chen; Cheng-Deng Kuo
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 7.  Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities.

Authors:  Mu-Su Pan; Jin Cao; Yue-Zu Fan
Journal:  Chin Med       Date:  2020-05-29       Impact factor: 5.455
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.